Table 1.
Baseline characteristics of the study population.
| Characteristic | Subgroup | Overall | Steroid-Free Population | Baseline Steroids | Intercurrent Steroids Non-Cancer-Related | Intercurrent Steroids Cancer-Related | p Value |
|---|---|---|---|---|---|---|---|
| (N = 413) | (N = 250) | (N = 114) | (N = 11) | (N = 38) | |||
|
Age
Median, range |
63 (30;92) |
63 (30;92) |
62 (34;85) |
68 (57;75) |
63 (42;80) |
0.38 | |
| Gender | F | 140 (34%) | 88 (35%) | 33 (29%) | 6 (55%) | 13 (34%) | 0.41 |
| M | 273 (66%) | 162 (66%) | 81 (71%) | 5 (45%) | 25 (66%) | ||
| Smoking history | current | 127 (31%) | 81 (33%) | 31 (27%) | 4 (36%) | 11 (30%) | 0.95 |
| former | 239 (59%) | 139 (57%) | 74 (66%) | 6 (55%) | 20 (55%) | ||
| never smoker | 39 (9%) | 25 (10%) | 8 (7%) | 1 (9%) | 5 (14%) | ||
| missing | 8 | 5 | 1 | 0 | 2 | ||
| Histology | Non squamous | 314 (76%) | 195 (78%) | 82 (72%) | 8 (72.7%) | 29 (76%) | 0.83 |
| Squamous | 99 (24%) | 55 (22%) | 32 (28%) | 3 (27.2%) | 9 (24%) | ||
| PD-L1 | negative | 67 (32%) | 42 (32%) | 18(31%) | 2 (25%) | 5 (36%) | 0.93 |
| positive ≥ 1% | 145 (68%) | 89 (68%) | 41 (69%) | 6 (75%) | 9 (64%) | ||
| missing | 201 | 119 | 55 | 3 | 24 | ||
| Stage | IIIB | 3 (0.7%) | 3 (1.2%) | 0 | 0 | 0 | 0.59 |
| IV | 410 (99.3%) | 247 (98.8%) | 114 | 11 | 38 | ||
| Metastatic sites | ≤2 | 188 (46%) | 123 (49%) | 47(41%) | 5 (45.4%) | 13 (34%) | 0.21 |
| >2 | 224 (54%) | 126 (51%) | 67 (59%) | 6 (54.5%) | 25 (66%) | ||
| missing | 1 | 1 | 1 | 0 | 0 | ||
| Brain metastases | No | 286(69%) | 192 (77%) | 56 (49%) | 6 (55%) | 32 (84%) | 0.12 |
| Yes | 127 (31%) | 58 (23%) | 58 (51%) | 5 (45%) | 6 (16%) | ||
| Liver metastases | No | 311 (75%) | 188 (75%) | 86 (75%) | 10 (90%) | 27 (71%) | 0.44 |
| Yes | 102 (25%) | 62 (25%) | 28 (25%) | 1 (10%) | 11 (29%) | ||
| Line of immunotherapy | 1–2 | 259 (63%) | 167 (67%) | 58 (51%) | 6 (55%) | 28 (74%) | 0.46 |
| >2 | 154 (37%) | 83 (33%) | 56 (49%) | 5 (45%) | 10 (26%) | ||
| ECOG PS | 0–1 | 313 (77%) | 207 (84%) | 72 (64%) | 8 (72.7%) | 26 (70%) | 0.09 |
| ≥2 | 95 (23%) | 40 (16%) | 41(36%) | 3 (27.2%) | 11 (30%) | ||
| missing | 10 | 3 | 5 | 0 | 1 |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status.